I
IX Biopharma Ltd
SGX:42C
IX Biopharma Ltd
SGX:42C
Price:
0.043 SGD
-10.42%
Market Closed
Updated:
May 8, 2024
IX Biopharma Ltd
Net Income (Common)
|
IX Biopharma Ltd
Net Income (Common) Peer Comparison
Comparables:
WVE
H02
H
1J5
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
I
|
IX Biopharma Ltd
SGX:42C
|
Net Income (Common)
-S$9.6m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
WAVE Life Sciences Ltd
NASDAQ:WVE
|
Net Income (Common)
-$57.5m
|
CAGR 3-Years
27%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
Haw Par Corporation Ltd
SGX:H02
|
Net Income (Common)
S$216.6m
|
CAGR 3-Years
22%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
H
|
Hyphens Pharma International Ltd
SGX:1J5
|
Net Income (Common)
S$8.6m
|
CAGR 3-Years
12%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
See Also
What is IX Biopharma Ltd's Net Income (Common)?
Net Income (Common)
-9.6m
SGD
-9.6m
SGD
Based on the financial report for Dec 31, 2023, IX Biopharma Ltd's Net Income (Common) amounts to -9.6m SGD.
What is IX Biopharma Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
9%
9%
Over the last year, the Net Income (Common) growth was 39%. The average annual Net Income (Common) growth rates for IX Biopharma Ltd have been -8% over the past three years , 9% over the past five years .
You don't have any saved screeners yet
